Internal Reference Number: FOI_8686
Date Request Received: 03/06/2025 00:00:00
Date Request Replied To: 21/07/2025 00:00:00
This response was sent via: By Email
Request Summary: dermatology and respiratory medicine
Request Category: Researcher
| Question Number 1: I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question: How many patients were treated in May 2025 (or latest available month) by the Dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Dupilumab (Dupixent) • Lebrikizumab (Ebglyss) • Omalizumab (Xolair) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq) • Nemolizumab (Nemluvio) | |
| Answer To Question 1: Please see below with date range of 1st June – 30th June 2025: • Abrocitininb = 0 • Baricitinib = 0 • Dupliumab = 13 • Lebrikizumab = <5 • Omalizumab = 10 • Tralokinumab = <5 • Upadacitinib = <5 • Nemolizumab = 0 | |
| Question Number 2: How many patients were treated in May 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: • Benralizumab (Fasenra) • Dupilumab (Dupixent) • Mepolizumab (Nucala) • Omalizumab (Xolair) • Reslizumab (Cinqaero) • Tezepelumab (Tezspire) | |
| Answer To Question 2: The only drug on the list used is Omalizumab. Six patients were treated in May 2025. | |
| To return to the list of all the FOI requests please click here |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
